Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia. Market research commissioned by Acasti* suggests there is an important market need for an effective, safe and well-absorbing omega-3 therapeutic with a positive impact on the major lipids associated with cardiovascular disease risk. Since August 2008, Acasti is focused on addressing this important unmet market need. Source
No articles found.
We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum a...
We're developing Vipax, the world's first porta...
We are developing nalbuphine ER to treat serious neurologically mediated condition...
We are developing nalbuphine ER to treat seriou...
The recognized global leader in neuromodulation devices to treat blindness, the co...
The recognized global leader in neuromodulation...
We are an international biotechnology company that is focused in the field of rege...
We are an international biotechnology company t...
Join the National Investor Network and get the latest information with your interests in mind.